Clinical trials: Major Depression Moderate
Treatment Resistant Depression, Major Depressive Disorder
pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression
Investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DMPFC for patients with treatment-resistant depression
- Trial name
- NCT05948839
- Testing
- active rTMS treatment
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Changping Laboratory
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depressive Disorder
Feasibility of Internet-delivered CBT for Adolescents With Depression
Prior to a properly powered randomized controlled study, evaluating efficacy and cost-effectiveness of ICBT, we will conduct a pilot study to investigate if the trial design is feasible, if therapist-guided and self-guided…
- Trial name
- NCT04117789
- Testing
- Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents, Self-guided internet-delivered cognitive behavior therapy for depression in adolescents, Treatment as usual
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Karolinska Institutet
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder, Bipolar Affective Disorder, Currently Depressed, Moderate
The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)
Patients belonging to Group 1 (Major Depression) and 2 (Bipolar Disorder) will be tested with psychometric and functional scales at baseline (T0) and after 4 weeks of pharmacological therapy (T1), to evaluate clinical and…
- Trial name
- RONIN (NCT06131268)
- Testing
- Venlafaxine
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Depressive Disorder, Major
Combining Data Sources to Identify Effect Moderation for Personalized Mental Health
This work will extend and apply methods for modeling heterogeneous treatment effects when multiple studies are available, with a particular focus on the complexities in mental health research.
- Trial name
- NCT05267873
- Testing
- Duloxetine, Vortioxetine
- Where
- United States
- Volunteers
- 9,586 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Depression, Suicide and Self-harm
Telehealth Behavioral Activation for Teens
Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to…
- Conditions
- Depression, Suicide and Self-harm, Depression in Adolescence, Depression Mild
- Trial name
- NCT06273995
- Testing
- Behavioral Activation
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Baylor College of Medicine
Depression, Unipolar
Whole-body Hyperthermia for Moderate to Severe Depressive Disorder
The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in addition to standard medical care in comparison to standard medical care alone on depressive symptom severity in patients with…
- Trial name
- HYPE2 (NCT03906149)
- Testing
- Whole-body hyperthermia + standard medical care, Standard medical care
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Universität Duisburg-Essen
Major Depressive Disorder
Home-Based Wearable rTMS Therapy for Moderate to Severe Depression
Background and Rationale With rapid economic development and increasing societal pressures, the incidence of neuropsychiatric disorders has risen annually, ranking as the leading cause of disability worldwide and imposing a…
- Trial name
- NCT07775586
- Testing
- rTMS-Tiny Treatment
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai Mental Health Center
Depression, Unipolar
Whole-body Hyperthermia for Mild to Moderate Depressive Disorder
The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in comparison to wait list on depressive symptom severity in patients with mild to moderate depressive disorder currently not under…
- Trial name
- HYPE1 (NCT03906175)
- Testing
- Whole-body hyperthermia
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Universität Duisburg-Essen
Major Depressive Disorder (MDD), IBNI617
Probiotic IBNI617 for Moderate to Severe Depression
IBNI617 is a live biotherapeutic product(LBP). This is a randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial to evaluate the efficacy and safety of IBNI617 in adult patients with major depressive…
- Trial name
- NCT07728253
- Testing
- Live biotherapeutic product
- Where
- China
- Volunteers
- 148 people
- Sponsor
- IBIOME BIOTECHNOLOGY CO., LTD